\-\ Texto\\:\\ \ \(0\)\
\-\ patient\\ had\\ abdominal\\ distension\\ and\\ a\\ mass\\ was\\ palpated\\ in\\ the\\ rlq\\.\\ abdomen\\ was\\ diffusely\\ tender\\ to\\ palpation\\.\\ no\\ rebound\\ or\\ guarding\\ was\\ noted\\.\\ bowel\\ sounds\\ were\\ diminished\\.\ \(0\)\
\-\ after\\ the\\ discovery\\ of\\ many\\ metastases\\ within\\ the\\ abdomen\\ on\\ ct\\,\\ the\\ patient\\ underwent\\ surgery\\ for\\ biopsy\\ and\\ resection\\ of\\ the\\ tumor\\.\\ tissue\\ was\\ removed\\ from\\ the\\ abdominal\\ mass\\ as\\ well\\ as\\ a\\ vaginal\\ nodule\\,\\ a\\ uterine\\ nodule\\,\\ a\\ rectosigmoid\\ nodule\\,\\ a\\ vena\\ cava\\ lymph\\ node\\ and\\ the\\ appendix\\.\\ the\\ abdominal\\ mass\\ tissue\\ was\\ partially\\ encapsulated\\,\\ lobulated\\ and\\ yellow\\-tan\\ in\\ appearance\\ with\\ a\\ size\\ of\\ 20cm\\ x\\ 11cm\\ x\\ 11cm\\.\\ the\\ mass\\ weighed\\ 1355g\\.\\ the\\ tumor\\ was\\ compatible\\ with\\ rhabdomyosarcoma\\ on\\ frozen\\ section\\.\\ the\\ patient\\ had\\ metastatic\\ disease\\ \\(group\\ iv\\)\\ and\\ was\\ subsequently\\ treated\\ with\\ systemic\\ chemotherapy\\ and\\ radiation\\.\\ at\\ 6\\ month\\ follow\\ up\\,\\ the\\ patient\\ had\\ no\\ evidence\\ of\\ new\\ metastasis\\ and\\ was\\ tolerating\\ chemotherapy\\.\ \(0\)\
\-\ x\\-ray\\ demonstrates\\ abdominal\\ distension\\.\ \(0\)\
\-\ ct\\ demonstrates\\ multiple\\ ovarian\\ metastases\\ throughout\\ the\\ abdomen\\,\\ including\\ the\\ liver\\,\\ and\\ large\\ bowel\\.\ \(0\)\
\-\ malignant\\ rhabdomyosarcoma\ \(0\)\
\-\ rhabdomyosarcoma\ \(41\)\
\-\ dysgerminoma\ \(2\)\
\-\ malignant\\ teratoma\ \(0\)\
\-\ embryonal\\ carcinoma\ \(7\)\
\-\ 15\\ y\\/o\\ presents\\ with\\ 2\\ month\\ history\\ of\\ abdominal\\ pain\ \(1\)\
\-\ rhabdomyosarcoma\\ is\\ a\\ frequent\\ cause\\ of\\ death\\ due\\ to\\ malignant\\ disease\\ in\\ children\\ and\\ is\\ the\\ most\\ common\\ soft\\ tissue\\ sarcoma\\ in\\ pediatrics\\.\\ roughly\\ 10\\%\\ of\\ all\\ solid\\ tumors\\ in\\ childhood\\ are\\ rhabdomyosarcomas\\.\\ these\\ tumors\\ are\\ extremely\\ malignant\\ and\\ tend\\ to\\ invade\\ locally\\ and\\ metastases\\ by\\ hematogenous\\ and\\ lymphatic\\ routes\\.\\ without\\ treatment\\,\\ 90\\%\\ of\\ patients\\ die\\ within\\ one\\ year\\ of\\ diagnosis\\.\\ rhabdomyosarcomas\\ are\\ equal\\ between\\ genders\\ and\\ are\\ bimodal\\ in\\ age\\ distribution\\ with\\ peaks\\ at\\ 4\\-6\\ years\\ and\\ 16\\-18\\ years\\ of\\ age\\.\\ these\\ tumors\\ are\\ thought\\ to\\ arise\\ from\\ totipotent\\ mesenchymal\\ cells\\ and\\ the\\ histologic\\ diagnosis\\ can\\ be\\ difficult\\.\\ histologic\\ types\\ that\\ can\\ be\\ seen\\ in\\ a\\ rhadomyosarcoma\\ include\\ alveolar\\,\\ embryonal\\,\\ embryonal\\-botryoid\\,\\ pleomorphic\\,\\ and\\ undifferentiated\\.\\ among\\ these\\ types\\,\\ the\\ alveolar\\ variety\\ has\\ the\\ worst\\ prognosis\\.\\ the\\ botyroides\\ type\\ has\\ the\\ classic\\ grape\\-like\\ appearance\\.\\ rhabdomyosarcomas\\ most\\ commonly\\ originate\\ from\\ the\\ pelvis\\ and\\ gu\\ tract\\ with\\ nearly\\ 40\\%\\ in\\ these\\ areas\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ rhabdomyosarcomas\\:\\ 0\\.07128451555768059\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.05184027211573075\ \(0\)\
\-\ 11cm\\:\\ 0\\.04752301037178706\ \(0\)\
\-\ malignant\\:\\ 0\\.03330103155125931\ \(0\)\
\-\ embryonal\\:\\ 0\\.031110490491876416\ \(0\)\
\-\ metastases\\:\\ 0\\.029520747574471574\ \(0\)\
\-\ histologic\\:\\ 0\\.02918771451377004\ \(0\)\
\-\ abdominal\\:\\ 0\\.028785973559597243\ \(0\)\
\-\ nodule\\:\\ 0\\.028481511584167167\ \(0\)\
\-\ alveolar\\:\\ 0\\.02750375394750507\ \(0\)\
\-\ distension\\:\\ 0\\.0267674976941048\ \(0\)\
\-\ tumors\\:\\ 0\\.025954579711621302\ \(0\)\
\-\ these\\:\\ 0\\.02397676217744302\ \(0\)\
\-\ yellow\\-tan\\:\\ 0\\.02376150518589353\ \(0\)\
\-\ 1355g\\:\\ 0\\.02376150518589353\ \(0\)\
\-\ genders\\:\\ 0\\.02376150518589353\ \(0\)\
\-\ 16\\-18\\:\\ 0\\.02376150518589353\ \(0\)\
\-\ totipotent\\:\\ 0\\.02376150518589353\ \(0\)\
\-\ rhadomyosarcoma\\:\\ 0\\.02376150518589353\ \(0\)\
\-\ embryonal\\-botryoid\\:\\ 0\\.02376150518589353\ \(0\)\
\-\ botyroides\\:\\ 0\\.02376150518589353\ \(0\)\
\-\ types\\:\\ 0\\.02351035648362798\ \(0\)\
\-\ was\\:\\ 0\\.021310566516737184\ \(0\)\
\-\ dysgerminoma\\:\\ 0\\.020800286078971397\ \(0\)\
\-\ grape\\-like\\:\\ 0\\.020800286078971397\ \(0\)\
\-\ abdomen\\:\\ 0\\.020469414524763044\ \(0\)\
\-\ 20cm\\:\\ 0\\.020024862703090587\ \(0\)\
\-\ routes\\:\\ 0\\.020024862703090587\ \(0\)\
\-\ rectosigmoid\\:\\ 0\\.01942339760520862\ \(0\)\
\-\ tolerating\\:\\ 0\\.01942339760520862\ \(0\)\
\-\ bimodal\\:\\ 0\\.01893196483756993\ \(0\)\
\-\ weighed\\:\\ 0\\.018516464352860338\ \(0\)\
\-\ die\\:\\ 0\\.018156541461689116\ \(0\)\
\-\ peaks\\:\\ 0\\.017839066972049268\ \(0\)\
\-\ frozen\\:\\ 0\\.017298175609617595\ \(0\)\
\-\ pediatrics\\:\\ 0\\.017298175609617595\ \(0\)\
\-\ invade\\:\\ 0\\.017063643596168458\ \(0\)\
\-\ undifferentiated\\:\\ 0\\.017063643596168458\ \(0\)\
\-\ originate\\:\\ 0\\.016847895057964857\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.016511837116662348\ \(0\)\
\-\ encapsulated\\:\\ 0\\.01646217849828649\ \(0\)\
\-\ tissue\\:\\ 0\\.016378068909320167\ \(0\)\
\-\ discovery\\:\\ 0\\.01628822022028765\ \(0\)\
\-\ \\%\\:\\ 0\\.016118498921935374\ \(0\)\
\-\ roughly\\:\\ 0\\.0159707457306478\ \(0\)\
\-\ locally\\:\\ 0\\.01582501198059315\ \(0\)\
\-\ are\\:\\ 0\\.015699108794199484\ \(0\)\
\-\ 4\\-6\\:\\ 0\\.01568675512240568\ \(0\)\
\-\ mesenchymal\\:\\ 0\\.015555245245938208\ \(0\)\
\-\ lymphatic\\:\\ 0\\.015310038296596627\ \(0\)\
\-\ x\\:\\ 0\\.01519712310160365\ \(0\)\
\-\ worst\\:\\ 0\\.015085290024523712\ \(0\)\
\-\ gu\\:\\ 0\\.015085290024523712\ \(0\)\
\-\ had\\:\\ 0\\.014909836813267184\ \(0\)\
\-\ hematogenous\\:\\ 0\\.014877847865127141\ \(0\)\
\-\ bowel\\:\\ 0\\.014447188856521614\ \(0\)\
\-\ age\\:\\ 0\\.014021079922071734\ \(0\)\
\-\ palpated\\:\\ 0\\.013956690739191679\ \(0\)\
\-\ month\\:\\ 0\\.013820024478709485\ \(0\)\
\-\ among\\:\\ 0\\.013686924004536739\ \(0\)\
\-\ variety\\:\\ 0\\.01362349948321546\ \(0\)\
\-\ years\\:\\ 0\\.013526917180692629\ \(0\)\
\-\ rlq\\:\\ 0\\.01332700111336552\ \(0\)\
\-\ appearance\\:\\ 0\\.013174698526871384\ \(0\)\
\-\ extremely\\:\\ 0\\.013111252575161915\ \(0\)\
\-\ tend\\:\\ 0\\.01305990973157514\ \(0\)\
\-\ childhood\\:\\ 0\\.012960068028932688\ \(0\)\
\-\ pleomorphic\\:\\ 0\\.012960068028932688\ \(0\)\
\-\ mass\\:\\ 0\\.012813595762237893\ \(0\)\
\-\ compatible\\:\\ 0\\.012725536015483553\ \(0\)\
\-\ nearly\\:\\ 0\\.012680982640951986\ \(0\)\
\-\ diminished\\:\\ 0\\.012594026139016081\ \(0\)\
\-\ guarding\\:\\ 0\\.012468635261293996\ \(0\)\
\-\ death\\:\\ 0\\.012428101899125426\ \(0\)\
\-\ section\\:\\ 0\\.012348819189674499\ \(0\)\
\-\ vena\\:\\ 0\\.012196924481989509\ \(0\)\
\-\ vaginal\\:\\ 0\\.012160251565397111\ \(0\)\
\-\ cava\\:\\ 0\\.012124070917601586\ \(0\)\
\-\ rebound\\:\\ 0\\.012053134776584406\ \(0\)\
\-\ equal\\:\\ 0\\.012053134776584406\ \(0\)\
\-\ group\\:\\ 0\\.011984017712936596\ \(0\)\
\-\ uterine\\:\\ 0\\.011818602763135268\ \(0\)\
\-\ diffusely\\:\\ 0\\.011632638149962893\ \(0\)\
\-\ lobulated\\:\\ 0\\.011573395813793687\ \(0\)\
\-\ frequent\\:\\ 0\\.011515427605650929\ \(0\)\
\-\ arise\\:\\ 0\\.011403102278425677\ \(0\)\
\-\ appendix\\:\\ 0\\.011217137665253302\ \(0\)\
\-\ systemic\\:\\ 0\\.011019219960253795\ \(0\)\
\-\ prognosis\\:\\ 0\\.0109254568441206\ \(0\)\
\-\ 90\\:\\ 0\\.010857214774082084\ \(0\)\
\-\ teratoma\\:\\ 0\\.010768832502321999\ \(0\)\
\-\ tumor\\:\\ 0\\.010739796774182271\ \(0\)\
\-\ most\\:\\ 0\\.010635229874544886\ \(0\)\
\-\ thought\\:\\ 0\\.010600314019892526\ \(0\)\
\-\ diagnosis\\:\\ 0\\.010578001783182857\ \(0\)\
\-\ node\\:\\ 0\\.010539740284442234\ \(0\)\
\-\ partially\\:\\ 0\\.010539740284442234\ \(0\)\
\-\ ovarian\\:\\ 0\\.010539740284442234\ \(0\)\
\-\ can\\:\\ 0\\.010448638018701184\ \(0\)\
\-\ subsequently\\:\\ 0\\.01044171428937249\ \(0\)\
\-\ removed\\:\\ 0\\.010384565481688925\ \(0\)\
\-\ x\\-ray\\:\\ 0\\.010384565481688925\ \(0\)\
\-\ distribution\\:\\ 0\\.01036578200644339\ \(0\)\
\-\ sarcoma\\:\\ 0\\.010255749676200115\ \(0\)\
\-\ from\\:\\ 0\\.01024072005245994\ \(0\)\
\-\ \\,\\:\\ 0\\.010215474170463675\ \(0\)\
\-\ tract\\:\\ 0\\.010202373322302056\ \(0\)\
\-\ difficult\\:\\ 0\\.01008179139820127\ \(0\)\
\-\ demonstrates\\:\\ 0\\.010062647987348712\ \(0\)\
\-\ children\\:\\ 0\\.009950281521733799\ \(0\)\
\-\ 40\\:\\ 0\\.009690465226113675\ \(0\)\
\-\ many\\:\\ 0\\.009466882792203295\ \(0\)\
\-\ tender\\:\\ 0\\.009348816423851831\ \(0\)\
\-\ lymph\\:\\ 0\\.00929795797559204\ \(0\)\
\-\ cells\\:\\ 0\\.009235705375067379\ \(0\)\
\-\ patient\\:\\ 0\\.009235492516618739\ \(0\)\
\-\ sounds\\:\\ 0\\.009186918200825822\ \(0\)\
\-\ 15\\:\\ 0\\.009186918200825822\ \(0\)\
\-\ solid\\:\\ 0\\.009186918200825822\ \(0\)\
\-\ in\\:\\ 0\\.009086732725396333\ \(0\)\
\-\ classic\\:\\ 0\\.008825484848539279\ \(0\)\
\-\ within\\:\\ 0\\.0087877703956123\ \(0\)\
\-\ commonly\\:\\ 0\\.008691459416322484\ \(0\)\
\-\ has\\:\\ 0\\.008650673695386944\ \(0\)\
\-\ metastasis\\:\\ 0\\.00862196044824778\ \(0\)\
\-\ throughout\\:\\ 0\\.00862196044824778\ \(0\)\
\-\ a\\:\\ 0\\.008552017289888976\ \(0\)\
\-\ iv\\:\\ 0\\.008405458052455779\ \(0\)\
\-\ pelvis\\:\\ 0\\.008369518616149943\ \(0\)\
\-\ including\\:\\ 0\\.008316492293781466\ \(0\)\
\-\ and\\:\\ 0\\.008248391098241816\ \(0\)\
\-\ biopsy\\:\\ 0\\.008171679896595042\ \(0\)\
\-\ new\\:\\ 0\\.008026382686793959\ \(0\)\
\-\ liver\\:\\ 0\\.007941297872864485\ \(0\)\
\-\ underwent\\:\\ 0\\.00790349335708415\ \(0\)\
\-\ the\\:\\ 0\\.007825431209639196\ \(0\)\
\-\ cause\\:\\ 0\\.0077931607184689115\ \(0\)\
\-\ 10\\:\\ 0\\.007764485790692481\ \(0\)\
\-\ type\\:\\ 0\\.007764485790692481\ \(0\)\
\-\ areas\\:\\ 0\\.007750261917105302\ \(0\)\
\-\ size\\:\\ 0\\.00772203738916111\ \(0\)\
\-\ palpation\\:\\ 0\\.007687167332474534\ \(0\)\
\-\ radiation\\:\\ 0\\.007558628705019775\ \(0\)\
\-\ disease\\:\\ 0\\.007529582432429673\ \(0\)\
\-\ follow\\:\\ 0\\.007318596959424351\ \(0\)\
\-\ between\\:\\ 0\\.007300527051817369\ \(0\)\
\-\ resection\\:\\ 0\\.007183061066092234\ \(0\)\
\-\ be\\:\\ 0\\.007103809829347327\ \(0\)\
\-\ as\\:\\ 0\\.006968072808054598\ \(0\)\
\-\ treated\\:\\ 0\\.006894476647126306\ \(0\)\
\-\ 6\\:\\ 0\\.006879030084568394\ \(0\)\
\-\ carcinoma\\:\\ 0\\.006528106927266487\ \(0\)\
\-\ all\\:\\ 0\\.006514618569895663\ \(0\)\
\-\ include\\:\\ 0\\.006461330156415868\ \(0\)\
\-\ ct\\:\\ 0\\.006443685463029881\ \(0\)\
\-\ y\\/o\\:\\ 0\\.0063790539887321855\ \(0\)\
\-\ one\\:\\ 0\\.0062418635668750515\ \(0\)\
\-\ at\\:\\ 0\\.0062413107969360275\ \(0\)\
\-\ up\\:\\ 0\\.006193658089094942\ \(0\)\
\-\ due\\:\\ 0\\.006146299603646468\ \(0\)\
\-\ evidence\\:\\ 0\\.006038928796137137\ \(0\)\
\-\ common\\:\\ 0\\.006027674425758483\ \(0\)\
\-\ patients\\:\\ 0\\.005961117518506809\ \(0\)\
\-\ metastatic\\:\\ 0\\.005798138554221268\ \(0\)\
\-\ soft\\:\\ 0\\.0056089670188505395\ \(0\)\
\-\ surgery\\:\\ 0\\.005592989391806671\ \(0\)\
\-\ noted\\:\\ 0\\.005459356303106721\ \(0\)\
\-\ without\\:\\ 0\\.005423216081827925\ \(0\)\
\-\ were\\:\\ 0\\.005229882309137254\ \(0\)\
\-\ well\\:\\ 0\\.005210460789672914\ \(0\)\
\-\ large\\:\\ 0\\.005036502511674069\ \(0\)\
\-\ 2\\:\\ 0\\.004959850394907133\ \(0\)\
\-\ multiple\\:\\ 0\\.004851229119890213\ \(0\)\
\-\ after\\:\\ 0\\.004765501893825344\ \(0\)\
\-\ presents\\:\\ 0\\.004705240688700609\ \(0\)\
\-\ treatment\\:\\ 0\\.004662040322374359\ \(0\)\
\-\ no\\:\\ 0\\.004638512941799472\ \(0\)\
\-\ to\\:\\ 0\\.004604507907741092\ \(0\)\
\-\ seen\\:\\ 0\\.004551556913929084\ \(0\)\
\-\ that\\:\\ 0\\.003978384713096559\ \(0\)\
\-\ on\\:\\ 0\\.003902377425150556\ \(0\)\
\-\ by\\:\\ 0\\.0038352315451344334\ \(0\)\
\-\ history\\:\\ 0\\.003181171260665993\ \(0\)\
\-\ of\\:\\ 0\\.0031402641724525187\ \(0\)\
\-\ is\\:\\ 0\\.0030312171341494647\ \(0\)\
\-\ pain\\:\\ 0\\.0028129600202984766\ \(0\)\
\-\ or\\:\\ 0\\.0026995222344035246\ \(0\)\
\-\ year\\:\\ 0\\.0025771031516790156\ \(0\)\
\-\ \\.\\:\\ 0\\.002200779865873219\ \(0\)\
\-\ for\\:\\ 0\\.001965251074508666\ \(0\)\
\-\ \\(\\:\\ 0\\.0019470666475575756\ \(0\)\
\-\ \\)\\:\\ 0\\.0019232821889846499\ \(0\)\
\-\ with\\:\\ 0\\.001892250826251586\ \(0\)\
